JP2025510678A5 - - Google Patents
Info
- Publication number
- JP2025510678A5 JP2025510678A5 JP2024555897A JP2024555897A JP2025510678A5 JP 2025510678 A5 JP2025510678 A5 JP 2025510678A5 JP 2024555897 A JP2024555897 A JP 2024555897A JP 2024555897 A JP2024555897 A JP 2024555897A JP 2025510678 A5 JP2025510678 A5 JP 2025510678A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody conjugate
- conjugate according
- pharmaceutically acceptable
- antibody
- fuc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22163928 | 2022-03-23 | ||
| EP22163928.9 | 2022-03-23 | ||
| PCT/EP2023/057565 WO2023180489A1 (en) | 2022-03-23 | 2023-03-23 | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510678A JP2025510678A (ja) | 2025-04-15 |
| JP2025510678A5 true JP2025510678A5 (cg-RX-API-DMAC10.html) | 2026-04-01 |
Family
ID=80930396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024555897A Pending JP2025510678A (ja) | 2022-03-23 | 2023-03-23 | カルシノエンビロニック抗原を発現する腫瘍を標的化するための抗体コンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250082770A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4496595A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025510678A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250024741A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119233830A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023237620A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3254964A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL315205A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024011519A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023180489A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3876998A1 (en) | 2018-11-05 | 2021-09-15 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
| EP4737483A1 (en) * | 2023-06-30 | 2026-05-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate production method including purification step using activated carbon material |
| WO2025238253A1 (en) * | 2024-05-16 | 2025-11-20 | Synaffix B.V. | Antibody-oligonucleotide conjugates |
| WO2026158363A1 (zh) * | 2025-01-22 | 2026-07-30 | 石药集团巨石生物制药有限公司 | 抗体-药物偶联物及其用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| GB9621295D0 (en) | 1995-12-07 | 1996-11-27 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| KR20050065587A (ko) | 2002-10-08 | 2005-06-29 | 이뮤노메딕스, 인코오포레이티드 | 항체 치료법 |
| WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
| NZ569204A (en) | 2005-12-21 | 2012-03-30 | Micromet Ag | Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA |
| US20070249014A1 (en) | 2006-02-10 | 2007-10-25 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| CA2770174A1 (en) | 2009-08-31 | 2011-03-03 | Roche Glycart Ag | Affinity-matured humanized anti cea monoclonal antibodies |
| ES2664989T3 (es) | 2010-10-01 | 2018-04-24 | National Research Council Of Canada | Anticuerpos ANTI-CEACAM6 y usos de los mismos |
| KR101981342B1 (ko) | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea 항체 |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| PT3199552T (pt) | 2012-11-20 | 2020-03-25 | Sanofi Sa | Anticorpos anti-ceacam5 e suas utilizações |
| US9567340B2 (en) * | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| EP3066470A4 (en) * | 2013-11-05 | 2017-05-31 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| EP3177633B1 (en) | 2014-08-04 | 2022-07-20 | SynAffix B.V. | Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
| EP3733209A1 (en) | 2014-10-03 | 2020-11-04 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| JP6815329B2 (ja) | 2015-03-23 | 2021-01-20 | バイエル ファーマ アクチエンゲゼルシャフト | 抗ceacam6抗体およびその使用 |
| CN107810273B (zh) | 2015-04-23 | 2022-09-27 | 西纳福克斯股份有限公司 | 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法 |
| WO2017137456A1 (en) * | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Bioconjugates containing sulfamide linkers for use in treatment |
| WO2017137457A1 (en) * | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates |
| WO2017137458A1 (en) * | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates |
| CA3026651A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| EP3720504A1 (en) | 2017-12-06 | 2020-10-14 | Synaffix B.V. | Enediyne conjugates |
| TWI920652B (zh) | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| KR20240104214A (ko) | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| RS64961B1 (sr) | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| AU2020350205A1 (en) | 2019-09-18 | 2022-05-12 | Lamkap Bio Alpha AG | Bispecific antibodies against CEACAM5 and CD3 |
| KR20230021018A (ko) | 2020-06-05 | 2023-02-13 | 재단법인 생물기술개발중심 | 항-메조텔린 항체를 함유하는 항체-약물 컨쥬게이트 및 이의 용도 |
| NL2026947B1 (en) | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
| CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁(苏州)生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| US12533419B2 (en) | 2021-07-19 | 2026-01-27 | Mabplex International Co., Ltd. | Antibody drug conjugate loaded with binary toxins and its application |
-
2023
- 2023-03-23 MX MX2024011519A patent/MX2024011519A/es unknown
- 2023-03-23 WO PCT/EP2023/057565 patent/WO2023180489A1/en not_active Ceased
- 2023-03-23 CN CN202380028865.6A patent/CN119233830A/zh active Pending
- 2023-03-23 AU AU2023237620A patent/AU2023237620A1/en active Pending
- 2023-03-23 IL IL315205A patent/IL315205A/en unknown
- 2023-03-23 EP EP23715080.0A patent/EP4496595A1/en active Pending
- 2023-03-23 JP JP2024555897A patent/JP2025510678A/ja active Pending
- 2023-03-23 CA CA3254964A patent/CA3254964A1/en active Pending
- 2023-03-23 KR KR1020247034723A patent/KR20250024741A/ko active Pending
-
2024
- 2024-09-20 US US18/892,256 patent/US20250082770A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510623A5 (cg-RX-API-DMAC10.html) | ||
| JP2023534131A5 (cg-RX-API-DMAC10.html) | ||
| EP0180564B1 (en) | Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents | |
| US5391723A (en) | Oligonucleotide conjugates | |
| JP2020114818A5 (cg-RX-API-DMAC10.html) | ||
| Jennings et al. | Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. | |
| JP5933923B2 (ja) | 新規な複合タンパク質及びペプチド | |
| Baldo et al. | C-reactive protein-like precipitins in plaice | |
| JP2024028453A5 (cg-RX-API-DMAC10.html) | ||
| US6800728B2 (en) | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents | |
| JP2024010112A5 (cg-RX-API-DMAC10.html) | ||
| JP2002513028A (ja) | ポリサッカリド抗原結合体 | |
| JP2021517113A5 (cg-RX-API-DMAC10.html) | ||
| JP2001506990A (ja) | 一価の(monovalent)抗体フラグメント | |
| IE58088B1 (en) | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency | |
| EP0206852A1 (fr) | Conjugué constitué d'une adhésine de paroi de Streptococcus mutans, de nature protéique et d'un polysaccharide de Streptococcus mutans, sa préparation et son utilisation notamment dans des vaccins anti-caries | |
| JP2012021161A (ja) | シアニン色素 | |
| JP2006514627A5 (cg-RX-API-DMAC10.html) | ||
| JP2025060958A5 (cg-RX-API-DMAC10.html) | ||
| JPH01230592A (ja) | T―抗原決定基を有する免疫吸着剤 | |
| JP2002504096A (ja) | タンパク質−多糖ワクチンの調製のための未修飾タンパク質とハロアシルまたはジハロアシル誘導体化された多糖との結合 | |
| JP2005530493A5 (cg-RX-API-DMAC10.html) | ||
| JP2008518953A5 (cg-RX-API-DMAC10.html) | ||
| JP2025510700A5 (cg-RX-API-DMAC10.html) | ||
| JP2004529881A5 (cg-RX-API-DMAC10.html) |